Therapy Department, Postgraduate Education Faculty, Ukrainian Medical Stomatological Academy, Poltava, Ukraine.
Dig Dis. 2009;27(4):550-4. doi: 10.1159/000233296. Epub 2009 Nov 4.
Questions concerning the diagnosis and treatment of ulcerative colitis (UC) in Ukraine are described. In recent years, there has been considerable progress in conservative therapy and new drugs have been developed that provide persistent remission of the inflammatory process after long-term application in many cases. The results of our own investigation on the efficiency of rebamipide in the complex treatment of UC patients are presented. Optimization of treatment with substitution of mesalazine in tablet or granule form, especially with an additional rebamipide prescription and a once-daily administration of budesonide, leads to an increased effectiveness of treatment and improvement of quality of life in UC patients. In the future, development of new approaches in the pharmacotherapy of UC will use medications as a basic therapy with the purpose of achieving high-quality and effective 'convalescence of mucous membrane', including cytoprotectors, bilious acids, endogenous substances, stabilization of membranes, antihypoxants and correction of microbiocenosis disorders.
本文描述了乌克兰溃疡性结肠炎(UC)的诊断和治疗问题。近年来,保守治疗方面取得了相当大的进展,并且开发了新的药物,这些药物在许多情况下经过长期应用后可使炎症过程持续缓解。本文介绍了我们关于瑞巴派特在 UC 患者综合治疗中的疗效的研究结果。通过替代美沙拉嗪片剂或颗粒剂的治疗优化,特别是增加瑞巴派特处方和布地奈德的每日一次给药,可提高治疗效果并改善 UC 患者的生活质量。未来,UC 的药物治疗新方法将使用药物作为基本治疗方法,目的是实现高质量和有效的“黏膜康复”,包括细胞保护剂、胆酸、内源性物质、膜稳定、抗缺氧剂和纠正微生物区系紊乱。